MetaCap

ImmuCell (ICCC) vs Trinity Biotech (TRIB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.

Summary

ImmuCell is the larger company by market cap ($88.0 million vs $5.5 million), about 16.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Head-to-head

ICCC versus TRIB key metrics
MetricICCCTRIB
Share price$9.69$6.75
Market cap$88.01M$5.49M
1-day change-2.81%-5.59%
YTD return+57.56%—
1-year return+50.23%—
5-year return+4.42%—
P/E ratio (TTM)138.43—
EPS (TTM)$0.07$-60.00
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
52-week high$12.10$52.50
52-week low$4.52$5.01
Distance from 52-week high-19.92%-87.14%
Average volume23.16K21.59K
Shares outstanding9.08M813.13K
SectorHealth CareHealth Care
IndustryBiotechnology: In Vitro & In Vivo Diagnostic SubstancesBiotechnology: In Vitro & In Vivo Diagnostic Substances

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ImmuCell is about 16.0 times larger than Trinity Biotech by market value ($88.01M vs $5.49M).

ICCC vs TRIB FAQ

Which is bigger, ImmuCell or Trinity Biotech?

ImmuCell (ICCC) is larger, with a market capitalization of $88.01M compared with $5.49M for Trinity Biotech (TRIB).

Are ImmuCell and Trinity Biotech in the same industry?

Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.

More comparisons